02 — AI & Search Visibility

Pharma SEO services built for
where patients and HCPs actually search.

Traditional SEO is now only part of the search landscape. Patients and HCPs increasingly encounter AI-generated answers before they reach a website. PharmaForward covers the full spectrum — paid, organic, AEO, and GEO — so your brand is present wherever the search actually happens.

60d
To AI Overview
citations
↓25%
Traditional search
volume decline
0
Competitors with
pharma AEO strategy
The landscape

Search has three channels now.
Most brands are in one.

For twenty years, biopharma search strategy meant one channel: Google blue links. That model still works. It just covers a shrinking share of how patients and HCPs actually find information.

Google AI Overviews answer health queries before any blue link. Perplexity and ChatGPT are used daily by physicians for clinical research. Your brand’s answer in those tools is either your content or a competitor’s.

60%+
of queries now include Google AI Overviews, according to 2026 industry data. Traditional search volume is projected to drop 25% as generative AI search becomes standard. The window to establish AI search presence before competitors is closing.

PharmaForward builds pharma SEO services across all three search channels — the foundation, the emerging layer, and the AI-native channel — within FDA fair balance requirements and MLR review timelines from day one.

Channel 01
SEO & Paid Search

Traditional search visibility — the foundation that everything else builds on. Organic rankings for branded and unbranded disease-state terms, paid search architecture that captures high-intent HCP and patient queries, and the technical infrastructure that signals authority to search engines.

Organic SEO Paid Search Technical SEO Competitive SoV
Channel 02
AEO — Answer Engine
Optimization

Structuring content to earn citations in Google AI Overviews and featured snippets — the answers that appear before any blue link. Requires MLR-compliant FAQ schema, structured content architecture, and E-E-A-T signals that Google's AI extraction layer trusts.

Google AI Overviews FAQ Schema Featured Snippets E-E-A-T
Channel 03
GEO — Generative Engine
Optimization

Earning citations in external AI tools — Perplexity, ChatGPT, Claude, Gemini. Distinct from AEO in that content must be authoritative enough for LLMs to surface it unprompted. Requires content depth, structured data, and domain authority that generative models can reference and attribute.

Perplexity ChatGPT Gemini LLM Citation
The problem

Your brand is invisible
in the answers that matter most.

A biopharma brand can rank first on Google and still be absent from every AI-generated answer a patient reads. The two are different infrastructure. Most biopharma brands have only invested in one.

The brands earning AI citations today started building structured, MLR-compliant content architecture 12-18 months ago. The window is still open — but it's closing faster in rare disease and gene therapy, where patient search volume concentrates around a small number of high-intent queries.

The technical work is the same foundation — schema markup, structured content, authority signals — applied deliberately to where AI is extracting answers.

You rank on Google but don’t appear in AI Overviews. Organic rankings and AI citations use different signals. A page can rank #1 and still be ignored by AI extraction if it lacks the structured data and content depth AI tools require.

Your unbranded disease-state terms are owned by generalist health sites. WebMD, Healthline, and NIH dominate AI citations for most disease states. The window to establish biopharma brand authority in these answers is narrow — but it exists, particularly for rare and orphan disease categories.

Your paid search is spending without an unbranded strategy. Most biopharma paid search budgets are heavily weighted toward branded terms. The patients who could most benefit from your treatment are searching unbranded disease-state terms first. That is the traffic you’re missing.

Your schema markup hasn’t been through MLR review. Schema markup for medical and pharmaceutical content requires FDA fair balance consideration and MLR review. Most schema implementations on biopharma sites were done by developers without either. That creates both compliance risk and missed citation opportunity.

Your HCP site is invisible to HCP search behavior. HCPs search differently than patients — clinical terminology, mechanism of action, dosing protocols. Most biopharma HCP sites are optimized for branded terms only, missing the unbranded clinical queries where prescribing decisions actually start.

What’s included

Full-spectrum pharma
search coverage.

Built within FDA fair balance requirements, MLR review timelines, and HIPAA-aware content architecture from day one.

Paid Search
Google Ads Architecture
Microsoft/Bing Ads Setup
HCP vs. Patient Campaigns
Unbranded Disease-State
Competitive Conquesting
Smart Bidding Strategy
Geo-Targeted Campaigns
Organic & Technical SEO
Technical SEO Audit
Content Architecture
Keyword Strategy
On-Page Optimization
Internal Linking Structure
Core Web Vitals
MLR-Compliant Content Briefs
AEO / Schema
MLR-Compliant JSON-LD
FAQPage Schema
MedicalCondition Schema
Drug Schema Markup
Organization Schema
Local / treatment center Schema
Featured Snippet Targeting
GEO / AI Visibility
AI Overview Monitoring
Perplexity Citation Tracking
LLM Content Optimization
E-E-A-T Signal Building
Authority Content Strategy
AI Citation Reporting
Competitive AI Share-of-Voice
Case study
Oncology · Unbranded disease-state · 60 days to citation

Google AI Overview citations within 60 days — for a brand that didn’t appear at all.

An oncology brand had strong organic rankings for its branded terms but was completely absent from AI-generated search results. When patients searched the disease state, the answers they read came entirely from generalist health sites. The brand had no presence in the answers that preceded every clinical conversation.

PharmaForward built an MLR-compliant schema markup infrastructure across the patient and HCP sites — FAQPage, MedicalCondition, and Drug schema — structured specifically for how Google AI extraction works. Alongside the schema work, we restructured key content pages to directly answer the unbranded queries patients and HCPs were using. Every piece of content went through the standard MLR review pipeline before deployment.

Within 60 days of launch, the brand earned its first Google AI Overview citations for three unbranded disease-state queries. Within 90 days, it appeared in Perplexity answers for two clinical queries. AI search presence, once zero, became a measurable channel with its own reporting track.

Therapy areaOncology — rare solid tumor
Timeline60 days to first citation
StackJSON-LD Schema · GA4 · AI Overview Monitoring
ComplianceMLR-reviewed · FDA fair balance · HIPAA-aware
AI search visibility index (0–100) — engagement start marked
82
Visibility score
at 90 days
60d
First AI Overview
citation
3
Schema types
deployed
How it works

Four phases. Full-spectrum search presence.

01
Search Visibility Audit

Two to three weeks. Organic share-of-voice, paid search architecture, schema markup status, and current AI citation presence across Google AI Overviews, Perplexity, and ChatGPT. Competitive gap analysis against key therapy-area comparators.

02
Technical & Schema Foundation

MLR-compliant JSON-LD schema markup across patient and HCP properties. Technical SEO remediation. Content architecture aligned to the queries patients and HCPs actually use — structured for both traditional ranking and AI extraction.

03
Paid Search Rebuild

Separate HCP and patient campaign architecture. Unbranded disease-state expansion beyond branded terms. Geo-targeting aligned to treatment center geography. Smart Bidding strategy validated against clean conversion data from the analytics foundation.

04
AI Citation Monitoring

Ongoing tracking of AI Overview presence, Perplexity citation frequency, and competitive AI share-of-voice. Monthly reporting that treats AI search as its own channel — not an afterthought in a traditional SEO report.

FAQ

Questions about
pharma SEO & AI search.

The questions biopharma marketing and digital teams ask most often about pharma SEO services and AI search visibility.

Related: Analytics & Measurement  ·  Marketing Optimization

What is pharma SEO? +
Pharma SEO is search engine optimization built specifically for pharmaceutical and biotech brands — accounting for FDA fair balance requirements, MLR review timelines, HIPAA-aware content architecture, and the dual audience of patients and HCPs who search with fundamentally different intent. Unlike consumer SEO, pharma SEO must balance discoverability with regulatory compliance at every implementation decision.
What is AEO for biopharma? +
AEO (Answer Engine Optimization) for biopharma means structuring content so AI tools like Google AI Overviews cite your brand when patients and HCPs ask health questions. It requires MLR-compliant structured data — FAQPage, MedicalCondition, and Drug schema — plus content architecture designed for how generative AI extracts and attributes answers. AEO is distinct from traditional SEO in that ranking position matters less than whether your content is structured for AI extraction.
What is GEO in pharma marketing? +
GEO (Generative Engine Optimization) is optimizing biopharma content to be cited by generative AI systems — ChatGPT, Perplexity, Google Gemini, Claude, and others. Where SEO earns blue-link rankings and AEO earns Google AI Overview positions, GEO earns citations in external AI tools that answer health questions directly. All three share the same technical foundation — structured data, content authority, and technical SEO — but GEO requires additional content depth and domain authority signals that LLMs can reference unprompted.
How does AI search change pharma marketing? +
Traditional search volume is declining as more than 60% of queries now include Google AI Overviews. For biopharma brands, patients and HCPs are increasingly reading AI-generated answers without clicking through to brand websites. A brand can rank first organically and still be absent from the answer a patient reads. Brands that build structured, MLR-compliant content architecture now will earn AI citations that competitors will struggle to displace — the first-mover window in pharma AI search is narrow but real.
What is the difference between SEO, AEO, and GEO for pharma? +
SEO optimizes for traditional Google and Bing search rankings. AEO (Answer Engine Optimization) optimizes for Google AI Overviews and featured snippets — answers that appear within Google itself before any blue link. GEO (Generative Engine Optimization) optimizes for citations in external AI tools like Perplexity and ChatGPT. All three share the same technical foundation but differ in content structure, schema requirements, and what signals each platform prioritizes for extraction and attribution.
Does schema markup need to go through MLR review? +
Yes — and most biopharma brands have not done this. Schema markup for pharmaceutical content makes structured claims about medical conditions, drugs, and treatments that are visible to search engines and AI tools. These claims are subject to FDA fair balance requirements and should go through the standard MLR review pipeline. PharmaForward builds schema markup with MLR review built into the workflow, not added as an afterthought.

Start with a
search visibility audit.

Two to three weeks. Organic share-of-voice, paid search architecture, schema markup, and your current presence — or absence — in AI-generated answers.

Connect with us